MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint

MT Newswires Live

Dec 16, 2024

MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.

The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.

No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.

MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491931366"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491931366\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491931366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491931366","market":"fut","top_or_hot":-1,"title":"MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.</p><p>The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.</p><p>No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.</p><p>MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-16 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.</p><p>The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.</p><p>No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.</p><p>MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491931366","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491931366","pubTimestamp":1734354015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MannKind  said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MNKD":"曼恩凯德生物医疗","BK4584":"避孕概念"},"translate_title":"MannKind表示吸入胰岛素Afrezza 3期研究的6个月结果达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}